Eli Lilly is banking that new drugs will counter the massive drop in profits from losing exclusivity of its top-selling antidepressant Cymbalta. The FDA already approved six less costly versions of the drug after its patent expired Dec. 11, 2013. The patent loss is expected to take a huge bite out of the medication’s multibillion-dollar profits. The drug generated Lilly sales of $4.2 billion between January 2012 and September 2012.